{"prompt": "['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', '\u00df2- and a much lower affinity (approximately 100-fold) for the 3-adrenoreceptor [50]. It possesses', 'no other autonomic nervous system activity. After complete -adrenoreceptor blockage, the NE', 'release in synapsis may only result in a-adrenoceptor activation, and thus propranolol is considered', 'as a weak indirect a-adrenoceptor agonist [51]. At dosages greater than required for \u00df blockade it', 'presents with strong membrane stabilizing activity. There is also an evidence that propranolol may', 'function as an antagonist of 5-HT 1A and 5-HT1B serotonin receptors [52].', 'After oral intake, propranolol undergoes rapid absorption in the intestine. It is highly lipophilic and', 'more than 90% bound with plasma proteins. Peak plasma concentrations occur about 1 to 4 hours', 'after an oral dose. Plasma half-life is 3 to 6 hours following single dose or 10 hours for extended', 'release tablets. Mean peak plasma concentration following a single oral dose of 40 mg and 160 mg is', '38 ng/ml and 200-245 ng/ml, respectively. The extended release tablets result in a peak of 18-50', 'ng/ml. Bioavailability after oral administration is within the range of 25-35% due to extensive first-', 'pass hepatic clearance and may be increased up by 50% during concomitant food intake with no', 'further change in time to peak concentration, plasma binding, half-life, or the amount of unchanged', 'drug in the urine. Propranolol crosses the blood-brain barrier and the placenta, and is distributed', 'into breast milk. Its volume of distribution is approximately 4 liters/kg. The metabolism of', 'propranolol takes place mainly in the liver and involves cytochromes P (CYPs) CYP2D6, CYP1A2 and', 'CYP2C19. Propranolol is also a substrate for the intestinal efflux transporter, p-glycoprotein.', 'Excretion is primarily renal, but about 1-4% of a dose is found in the faeces as unchanged drug and', 'metabolites. Propranolol plasma clearance is reduced in elderly and Caucasians, as well as in patients', 'with chronic renal failure and cirrhosis. Blood levels of propranolol may be increased by co-', 'administration with substrates or inhibitors of CYP2D6 (i.e. amiodarone, cimetidine, delavudin,', 'fluoxetine, paroxetine, quinidine, and ritonavir), CYP1A2 (i.e. imipramine, cimetidine, ciprofloxacin,', 'fluvoxamine, isoniazid, ritonavir, theophylline, zileuton, zolmitriptan, and rizatriptan), and CYP2C19', '(i.e. fluconazole, cimetidine, fluoxetine, fluvoxamine, tenioposide, and tolbutamide). Blood levels of', 'propranolol may be decreased by co-administration with CYP inducers such as rifampin, ethanol,', 'phenytoin, phenobarbital and cigarette smoking. Propranolol is not significantly dialyzable [53-56].', '1.2.2 Current Indications and Dosing', 'Currently, propranolol is used in the treatment of hypertension, angina pectoris, cardiac', 'dysrhythmias, tachycardia, anxiety, thyrotoxicosis, infantile hemangiomas (IH), and essential tremor.', 'It is used in prophylaxis of migraine and upper gastrointestinal tract bleeding in patients with portal', 'hypertension as well as for the long term prevention of sudden cardiac death in patients who have', 'shown evidence of dysrhythmias during the acute phase of myocardial infarction.', 'Usually, the initial propranolol dose in adults is 40 mg two or three times daily and may be increased', 'by the same amount at weekly intervals to a maximum daily dose of 320 mg (immediate-release', 'tablets). If it is necessary to withdraw propranolol, this should be done gradually, or another \u00df-', 'adrenergic receptor blocker should be substituted [53, 57].', '1.2.3 Antineoplastic Potential', 'Pre-clinical studies revealed wide antineoplastic potential of propranolol that includes inhibiton of', 'proliferation, migration, invasion and angiogenesis, as well as induction of apoptosis, treatment', 'sensitization and immunomodulation. Propranolol decreased proliferation rate associated with', 'Page 17 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'catecholamines or isoproterenol in colorectal, pancreatic and lung adenocarcinoma cancer cells [58-', '60]. In oral squamous cell carcinoma cells proliferation was induced via \u00df2 signalling pathway', 'activated by IL-6 after stimulation of NE and isoproterenol. Then the proliferation rate was inhibited', 'by IL-6 specific antibody and propranolol [61]. Similarly, a decreased level of IL-6 concomitantly with', 'inhibition of metastatic growth was reported in a murine melanoma model after propranolol', 'treatment [62]. Propranolol was more potent in reducing the proliferation, migration, and invasion of', 'non-stimulated breast, colon, and hepatocellular cancer cells than the selective \u00df1 receptor agonist,', 'atenolol [63]. Propranolol inhibited the NE-induced upregulation of MMP-2 and MMP-9 which are', 'responsible for tissue remodeling process. This resulted in decreased tumour invasion of breast', 'cancer, ovarian cancer, nasopharyngeal carcinoma, pancreatic cancer, gastric adenocarcinoma,', 'melanoma, prostate cancer and IH [64-71]. NE induces EMT via TGF-B-adrenoreceptor pathway that', 'leads to increased metastatic potential and this effect was shown to be inhibited in colorectal cancer', 'cell lines by propranolol [72]. In breast cancer cell lines, isoproterenol reduced Rap1-dependent cell-', 'cell adhesion and promoted cell migration, whereas propranolol reduced the level of migration [73].', 'Catecholamine signaling was also reported to increase breast cancer cell colonization of bone via', 'upregulation of receptor activator of nuclear factor kappa-B ligand (RANKL), which was reversed by', 'propranolol or the RANKL inhibitor denosumab [74]. Propranolol induced cell cycle arrest and', 'apoptosis in gastric carcinoma cell lines that was associated with a decrease of NF-kB, VEGF,', 'cyclooxygenase (COX) 2, MMP-2 and MMP-9 expression [68]. The pro-apoptotic effect of propranolol', 'was observed in head and neck squamous cell carcinoma and neuroblastoma cell lines and was', 'connected to increased expression of p53 and p73 proteins [75, 76]. In another study on', 'hemangioblastoma cells from vHL patients, propranolol decreased the viability and increased', 'apoptosis that was associated with a decreased the expression of HIF protein and its target genes', '[77]. In ovarian cancer cell lines, propranolol blocked the angiogenesis by decreasing the VEGF', 'expression which was previously stimulated by -adrenergic agonists. Catecholamine induction of', 'PKA-dependent signaling pathway was identified as a major mechanism by which behavioural stress', 'enhanced tumour angiogenesis [78]. Propranolol inhibited brain endothelial cells tubulogenesis and', 'matrix MMP-9 secretion in human glioblastoma [79]. HIF-1a expression was reported to be', 'upregulated by NE, via the CAMP/PKA/Akt/p70S6K pathway, whereas propranolol completely', 'abolished induction of VEGF expression and HIF-1a protein amount by NE and resulted in decreased', 'angiogenesis in various cancer cell lines [80]. Propranolol also exhibited a potential to revert drug', 'resistance of some leukemia cell lines to doxorubicin and revealed synergistic role with paclitaxel and', '5-fluorouracil in number of human cancer and non-cancer cell lines [81, 82]. Catecholamines were', 'reported to reduce NK cell and cytotoxic T lymphocyte numbers as well as tumour necrosis factor', 'alpha (TNF) and IFN-y levels and this could be reversed by propranolol [83-85].', 'A positive effect of propranolol on cancer has been observed in epidemiological studies that assessed', 'hypertensive and non-hypertensive patients. The study of Chang et al. compared 12119 patients', 'treated with propranolol for more than 6 months to 12119 non-propranolol users over a 12 year', 'period. Overall, the incidence for developing cancer was lower in the propranolol cohort (HR: 0.75;', '95% CI: 0.67-0.85; p<0.001). Site specific analysis showed a decreased risk in head and neck cancers', '(HR=0.58; 95% CI: 0.35-0.95), oesophagus (HR=0.35; 95% CI: 0.13-0.96), stomach (HR=0.54; 95% CI:', '0.30-0.98), colon (HR=0.68; 95% CI: 0.49-0.93), and prostate cancers (HR=0.52; 95% CI: 0.33-0.83)', '[86]. The study of Nkontchou showed that the use of propranolol in patients with cirrhosis due to', 'Page 18 of 60']\n\n###\n\n", "completion": "END"}